Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 27, 2026

Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in clinical practice; largest dataset spans more than 12,000 patients Clinical abstracts further characterize the positive effects of Rezdiffra on noninvasive measures of treatment response, cardiovascular risk markers and patient-reported outcomes CONSHOHOCKEN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that new clinical and real-world evidence (RWE) evaluating Rezdiffra and its growing impact on patient care will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place Nov. 5-9 in Denver.

GlobeNewsWire • Oct 27, 2026

Baron Health Care Fund: Q3 2026 New Positions And Exits

During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.

Seeking Alpha • Oct 26, 2026

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to the open of the U.S. financial markets.

GlobeNewsWire • Oct 20, 2026

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

Madrigal Pharmaceuticals is transitioning from hypergrowth to a self-funding franchise, with Rezdiffra now covering enterprise costs ahead of key 2027 data. Q2 net sales grew 71% to $364.3M, with over 50,000 patients on Rezdiffra and gross margins at 89%, indicating strong underlying fundamentals and low market penetration (~11%). Despite a headline loss, recurring cash operations are breakeven or slightly positive, and cash balances increased, supporting ongoing commercial and pipeline investments.

Seeking Alpha • Oct 20, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Oct 15, 2026

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).

GlobeNewsWire • Oct 6, 2026

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.

The Motley Fool • Sep 10, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha • Sep 10, 2026

Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference

CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept.

GlobeNewsWire • Sep 2, 2026